MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

1.590
-0.010
-0.63%
Opening 11:57 05/11 EDT
OPEN
1.580
PREV CLOSE
1.600
HIGH
1.680
LOW
1.550
VOLUME
63.69K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
0.8600
MARKET CAP
45.42M
P/E (TTM)
-3.3257
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 4h ago
Navidea Bio reports NIH grant to evaluate Tc99m tilmanocept as a kidney imaging agent
Navidea Biopharmaceuticals (NAVB) announces the granting of a National Institutes of Health ((NIH)) award to the University of California San Diego School of Medicine for the proposal entitled, “Renal Molecular
Seekingalpha · 4h ago
Navidea Biopharmaceuticals Announces NIH Grant Award To UC San Diego For Clinical Study Evaluating Tc99m Tilmanocept As A Kidney Imaging Agent; Size Not Disclosed
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the
Benzinga · 4h ago
Earnings Scheduled For May 11, 2021
  Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.
Benzinga · 7h ago
Global Sentinel Node Biopsy Market Size and Share By Industry Demand, Worldwide Research, Prominent Players, Emerging Trends, Investment Opportunities and Revenue Expectation till 2026
May 10, 2021 (The Expresswire) -- The Sentinel Node Biopsy Marketresearch report offers the breakdown of the industry by market size, rate of development,...
The Express Wire · 1d ago
Allred Capital Management, LLC Buys iShares Russell 1000 ETF, PIMCO Enhanced Short Maturity ...
GuruFocus News · 4d ago
Nanopharmaceuticals - A Regulatory Framework
May 06, 2021 (Market Insight Reports) -- Nanopharmaceuticals play a major role in advance healthcare, as it is widely used in drug delivery....
Market Insight Reports · 5d ago
8-K: NAVIDEA BIOPHARMACEUTICALS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- PURSUANT TO SECTION 13 OR 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NAVB. Analyze the recent business situations of NAVIDEA BIOPHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NAVB stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 742.82K
% Owned: 2.60%
Shares Outstanding: 28.57M
TypeInstitutionsShares
Increased
7
158.08K
New
5
36.74K
Decreased
8
25.91K
Sold Out
24
84.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.13%
Pharmaceuticals & Medical Research
-0.27%
Key Executives
Chairman/Independent Director
Michael Rice
Chairman/Director
S. Kathryn Rouan
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
Amit Bhalla
Director
Malcolm Witter
Independent Director
Claudine Bruck
Independent Director
Kathy Rouan
No Data
  • All
  • Financials
  • Insiders
More
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.